Recovery and Symptom Relief Following Percutaneous Ablation of Abdominal Wall Endometriosis

Status

Enrolling by invitation

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06268951

Enrollment

Registered

2024-02-21

Start date

2024-05-09

Completion date

2028-12-01

Last updated

2026-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Keywords

Abdominal Wall endometriosis

Brief summary

To determine the characteristics of recovery and symptom relief following ablation of abdominal wall endometriosis.

Detailed description

The purpose of this study is to characterize the recovery and symptom relief following cryoablation of abdominal wall endometriosis. Patients undergoing clinically indicated ablation of abdominal wall endometriosis will receive an endometriosis-specific symptom survey (Endometriosis Health Profile - 30) prior to ablation and then at 3-, 6-, 12-, and 24-months following treatment. A 2 question survey related to pain at the treatment site will also be administered prior to ablation and then at 1-, 7-, and 30-days after ablation.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Undergoing ablation for abdominal wall endometriosis.

Exclusion criteria

* Decline to participate in research.

Design outcomes

Primary

Measure	Time frame	Description
Symptom severity due to abdominal wall endometriosis following ablation.	Baseline and intermittently over 24 months	Using the Endometriosis Health Profile - 30 survey, the impact of ablation on endometriosis-related symptoms will be quantified over time. A numerical rating scale will be used to quantify pain at the site of treated abdominal wall endometriosis.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORThomas Atwell, M.D.

Mayo Clinic

Outcome results